Neurome, Inc. is a discovery stage biotechnology company that seeks therapeutic solutions to human neurodegenerative diseases. The company focuses its efforts on Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) - usually fatal neurodegenerative disorders that are currently untreatable and share characteristics which make them particularly amenable to Neurome's expertise and technologies. Neurome has developed and optimized proprietary technologies to reveal and quantify gene expression patterns and the resultant morphological details of brain structures in normal and pathological brains with an unprecedented level of sensitivity, specificity and resolution. Neuromeâs unique technologies to measure and assess neurodegenerative processes at work â at the molecular, cellular and macroscopic levels â are ideally suited to identify the earliest evidence of pathology in models of human diseases of the Central Nervous System, as well as to evaluate the comparative effectiveness of pharmaceutical candidates for intervention. The company dedicates these technologies to discovery and development of drugs to provide effective treatments for diseases characterized by neurodegenerat
